ATTENTION: The software behind KU ScholarWorks is being upgraded to a new version. Starting July 15th, users will not be able to log in to the system, add items, nor make any changes until the new version is in place at the end of July. Searching for articles and opening files will continue to work while the system is being updated.
If you have any questions, please contact Marianne Reed at mreed@ku.edu .
Population pharmacokinetic analysis of enrofloxacin and its active metabolite ciprofloxacin after intravenous injection to cats with reduced kidney function
dc.contributor.author | Foster, Jonathan D. | |
dc.contributor.author | Abouraya, Mahmoud | |
dc.contributor.author | Papich, Mark G. | |
dc.contributor.author | Muma, Nancy A. | |
dc.date.accessioned | 2024-06-24T16:24:26Z | |
dc.date.available | 2024-06-24T16:24:26Z | |
dc.date.issued | 2023-09-20 | |
dc.identifier.citation | Foster JD, Abouraya M, Papich MG, Muma NA. Population pharmacokinetic analysis of enrofloxacin and its active metabolite ciprofloxacin after intravenous injection to cats with reduced kidney function. J Vet Intern Med. 2023 Nov-Dec;37(6):2230-2240. doi: 10.1111/jvim.16866. Epub 2023 Sep 20. PMID: 37728198; PMCID: PMC10658592 | en_US |
dc.identifier.uri | https://hdl.handle.net/1808/35201 | |
dc.description.abstract | Background It is unknown if enrofloxacin accumulates in plasma of cats with reduced kidney function.Hypothesis To determine if enrofloxacin and its active metabolite ciprofloxacin have reduced clearance in azotemic cats.Animals Thirty‐four cats hospitalized for clinical illness with variable degree of kidney function.Methods Prospective study. After enrofloxacin (dose 5 mg/kg) administration to cats, sparse blood sampling was used to obtain 2 compartment population pharmacokinetic results using nonlinear mixed‐effects modeling. Plasma enrofloxacin and ciprofloxacin concentrations were measured and summed to obtain the total fluoroquinolone concentration. A model of ciprofloxacin metabolism from enrofloxacin was created and evaluated for covariate effects on clearance, volume of distribution, and the metabolic rate of ciprofloxacin generation from enrofloxacin.Results Body weight was the only covariate found to affect total fluoroquinolone volume of distribution (effect 1.63, SE 0.19, P < .01) and clearance (effect 1.63, SE 0.27, P < .01). Kidney function did not have a significant effect on total fluoroquinolone clearance (median 440.8 mL/kg/h (range 191.4‐538.0 mL/kg/h) in cats with normal kidney function, 365.8 mL/kg/h (range 89.49‐1092.0 mL/kg/h) in cats with moderate kidney dysfunction, and 308.5 mL/kg/h (range 140.20‐480.0 mL/kg/h) in cats with severe kidney dysfunction (P = .64). Blood urea nitrogen concentration influenced the metabolic generation of ciprofloxacin from enrofloxacin (effect 0.51, SE 0.08, P < .01), but other markers of kidney function did not.Conclusions and clinical importance. Adjustment of enrofloxacin dosage is not indicated for azotemic cats. | en_US |
dc.publisher | Wiley Open Access | en_US |
dc.rights | Copyright © 2023 The Authors. Journal of Veterinary Internal Medicine published by Wiley Periodicals LLC. on behalf of the American College of Veterinary Internal Medicine. This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited. | en_US |
dc.rights.uri | https://creativecommons.org/licenses/by/4.0/ | en_US |
dc.subject | Drug prescribing | en_US |
dc.subject | Feline | en_US |
dc.subject | Fluroquinolone | en_US |
dc.subject | Renal failure | en_US |
dc.title | Population pharmacokinetic analysis of enrofloxacin and its active metabolite ciprofloxacin after intravenous injection to cats with reduced kidney function | en_US |
dc.type | Article | en_US |
kusw.kuauthor | Muma, Nancy A. | |
kusw.kudepartment | Department of Pharmacology and Toxicology | en_US |
dc.identifier.doi | 10.1111/jvim.16866 | en_US |
dc.identifier.orcid | https://orcid.org/0000-0001-7300-0587 | en_US |
dc.identifier.orcid | https://orcid.org/0000-0002-7591-7898 | en_US |
kusw.oaversion | Scholarly/refereed, publisher version | en_US |
kusw.oapolicy | This item meets KU Open Access policy criteria. | en_US |
dc.identifier.pmid | PMC10658592 | en_US |
dc.rights.accessrights | openAccess | en_US |
Files in this item
This item appears in the following Collection(s)
-
Temporary Holding Space--Published Papers, Presentations, etc. [21]
Temporary holding space for new items -- to be used if the proper Community and Collection are not yet visible. Items will be relocated to the proper community/collection.
Except where otherwise noted, this item's license is described as: Copyright © 2023 The Authors. Journal of Veterinary Internal Medicine published by Wiley Periodicals LLC. on behalf of the American College of Veterinary Internal Medicine.
This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.